



CB SCIENTIFIC, INC.
Quarterly Information and Disclosure Statement
(UNAUDITED)
For the three month ended
December 31, 2016



OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

CB SCIENTIFIC, INC.

The Company was known as NET:X AMERICA INC. until it changed its name to CB SCIENTIFIC INC. on 12-14-2015

2) Address of the issuer's principal executive offices

Company Headquarters
10901 Roosevelt Blvd, Suite 1000c,
Saint Petersburg, FL, 33716
Phone: (720) 370-3554
Email: info@cbscientific.com
Website(s): www.cbscientific.com

IR Contact
investors@cbscientific.com

3) Security Information

Trading Symbol: CBSC

Exact title and class of securities outstanding:

CUSIP: 640930202

Par or Stated Value: 0.001

Total shares authorized: 1000,000,000 as of: 12/31/2016

Total shares outstanding: 57,105,263 as of: 12/31/2016

Additional class of securities (if necessary):

Trading Symbol: None

Exact title and class of securities outstanding: Series A Preferred

CUSIP: 640930202

Par or Stated Value: 0.001

Total shares authorized: 100,000,000 as of: 12/31/2016

Total shares outstanding: 10,000,000 as of: 12/31/2016

Transfer Agent

ClearTrust, LLC

16540 Pointe Village Dr.

Suite 206

Lutz, FL 33558

P: 813.235.4490 | F: 813.388.4549



Is the Transfer Agent registered under the Exchange Act?* Yes: X No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

The 1 for 75 reverse split, name and symbol change for Net X America Inc. (NXAM) to CB Scientific Inc. was announced 2/12/2016 on the Daily List. This corporate action was in effect on 2/16/2016.

4) Issuance History

The Company issued an initial issuance of common stock with the name change and recapitalization based on the asset purchase agreement by CB Scientific Inc. of Oregon (NET:X America) of CB Scientific Inc. of Colorado from its shareholders including FutureWorld Corp. The following common shares were issues as restricted securities and were issued in private issuances and did not require a registration and it is based on rule 144 exemption.

Talari Industries, LLC. *	46,255,263	Restricted
FutureWorld Corp.	8,000,448	Restricted
Zbigniew Lambo	1,000,000	Restricted
Zbigniew Lambo	1,849,552	Restricted

* Sam Talari is the sole director of Talari Industries, LLC and the CEO of FutureWorld Corp.

The Company has no other issuance of debt, private or public offerings, options, and warrants up to this date.

- A. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

All common and preferred share issuances by the issuer up to December 31, 2016 were initially issued as restricted in accordance with Rule 144. Each certificate had a standard restricted legend stamp.

5) Financial Statements



Incorporated by reference. See Quarterly Report - for the three months ended December 31, 2016.

6) Describe the Issuer's Business, Products and Services

A. a description of the issuer's business operations;

The address of our executive offices is: 10901 Roosevelt Blvd, Suite 1000c, Saint Petersburg, FL 33716 and our telephone number at that address is (720) 370-3554. The address of our web site is www.cbscientific.com. The information at our web site is for general information and marketing purposes and is not part of this report for purposes of liability for disclosures under the federal securities laws.

CB Scientific Inc. (CBSC), an Oregon corporation, through its subsidiaries, designs, develops and manufactures Life Science Analytical Tools and Devices, laboratory services, personal analytical kits and devices and CBD hemp oil and nutraceutical formulations for growers, care takers, dispensaries and companies worldwide. CB Scientific, through its subsidiaries, provides personal and professional THC and CBD test kits, pharmaceutical grade CBD oil solutions, SafeVape vaporizers for legal medicinal & recreational cannabis. CB Scientific and its subsidiaries do not grow, distribute or sell marijuana.

CB Scientific Inc. is seeking to acquire minority or full interest in currently operating companies and disruptive technologies in the Industrial Hemp/Medical and Recreational Cannabis Industry globally; such as vaporizers, lab testing, CBD oil, testing kits, dispensaries and other needed components. Our goal is to provide our acquired companies, current and future shareholders a clear strategy for the growth of their companies and their investment in those companies.

We currently provide multiple products that supply the burgeoning cannabis industry. The "picks and shovel" business model capitalizes of selling enterprises associated with the Industrial Hemp and Medical Cannabis industries products that are essential in their success. Our products solve long standing problems in testing, processing, and retail sales for industrial hemp and medical cannabis. The following divisions will continue to delve even further into purchasing existing products or developing brand new products as the wholesale and retail space continues to evolve. In addition, one primary focus is to manufacture, market, and sell products containing hemp derived CBD oil. We are invested in the following portfolio companies as subsidiaries;

NutraCann Labs, Inc. - URVape, Inc. - CB Scientific, Inc. (Colorado)

NutraCann Labs Inc.

CBD Oil- CBD is one of at least 60 cannabinoids found in hemp, and is non-psychoactive. The Cannabidiol "CBD" is a compound in cannabis that has significant medical effects, but does not make people feel "high" and can actually counter the psychoactive effects of THC. The reduced psychotropic of CBD-rich cannabis makes it an appealing treatment option for patients seeking anti-inflammatory, anti-pain, anti-anxiety, anti-psychotic, and/or anti-spasm effects without disconcerting lethargy. Scientific and clinical studies underscore CBD's potential as a treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuro-protective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere.



The present usage for CBD oil in the United States is estimated to be approximately 1,000-2,000 Kilograms a year and growing and with a yearly value of around \$200,000,000. Currently, the apparent current competitors are; CannaVest, Inc. and Medical Marijuana, Inc., which own portions of each other's companies, are the primary supplier of CBD oil in the United States. They supply the product in bulk to affiliate distributors and sell it retail in plastic tubes that are refined up to three levels. Real Scientific Hemp Oil™ is their trademark name.

NutraCann Labs has sourced its own CBD oil from Europe. We are also developing plans to fund an overseas hemp cultivation project to provide a consistent and reliable supply to the United States and beyond. Currently, industrial hemp cultivation is legal in twenty countries around the world. NutraCann's products are sold under the brand name "cbdessence" on CBDESSENCE.COM and DAVA.

NutraCann Labs will process the CBD oils that will be sold through our online presence for retailing industrial hemp oil-based Cannabidiol (CBD) nutritional supplements, wellness and personal care products and vapable CBD oils. NutraCann Labs will market items such as CBD oil, CBD infused edibles & multiple hemp related items and cross market our vaporizers from URVape.com. NutraCann Labs will be featuring scientific grade hemp oil which is highly sought after around the world. We will sell already recognizable brands including our own brands and drive internet sales through ads, videos, social media and Search Engine Optimization.

The global Nutraceutical market is projected to be in excess of \$200 billion by 2015 and the current US Nutraceutical and Dietary supplement market is valued at around \$42 billion. CBDESSENCE.com and URCBDOil.com will be at the forefront of this massive marketplace with significant opportunities. Cannabinoids (non-psychoactive CBD) have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of a wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and auto-immune diseases. Cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic events, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and HIV dementia. CBDESSENCE.com and URCBDOil.com will assist CB Scientific to generate positive cash flow for both URVape and our CBD oil and CBD infused products offered by NutraCann Labs.

CB Scientific, Inc.

CB Scientific, Inc. a wholly owned subsidiary based in Denver Colorado has developed new technologies specifically for cannabis analytics. CB Scientific introduced the first ever personal cannabinoid detection kits. These kits test all your products in-house and at your own convenience. These tests are quick, easy, and effective. CB Scientific's new PERSONALANALYTICS THC & CBD detection kit is the first simple, quick and accurate consumer THC & CBD test which will give you're an accurate reading of THC or CBD in any product you purchase, manufacture, or grow While many medical and recreational products are sold with cannabinoid levels listed, these numbers are often not representative of what is being sold.

URVape, Inc.

URVape™ is our brand name vaporizer pen which is sold with a charger and refill bottles. We market the product at URVape.com. It is our own trademarked vaporizer being marketed and sold online and in retail shops. The product is cutting edge design and requires puffing on the pen to facilitate battery use. The URVape vaporizing pen is sleek and lightweight. URVape will initially have oil vaporizers available and dry herb versions available in the coming months.

URVape was started to contribute to the current revolution, which has become an international phenomenon, known as the "Vaping" industry. URVape began test marketing OEM branded, off-the-shelf oil vaporizers, whose design and utility was well received, and which promulgated our first vendor agreement in the state of Colorado.



After studying the marketplace, with more than 466 vendors attempting to reach nicotine consumers, we recognized early on that there were unsupported claims and deficiencies in the products and e-liquids being sold. Product deficiencies were noted in the devices being used in combination with e-liquids, which, together could be producing harmful elements. Consequently, these elements are being inhaled as a result of heating the contents of the e-liquids, thereby producing potentially harmful changes to the initial ingredients. As a result, URVape has dedicated itself to providing products that are free of any substances which, when heated for vaping, could be harmful.

URVape has entered into an exclusive Non-disclosure/Non-compete contract with one of the foremost international vaping products manufacturers. Through our in-house Product Development personnel, and through the hiring of a consultant whose area of expertise is microbiology, specific to cannabis and vaping, we have developed two primary device changes that are being patented. These changes are designed to produce safe devices, built with safe materials, and to exact temperature specifications suited to a variety of e-liquids that we will bring to market.

We are also developing new methods of producing, packaging and flavoring a variety of e-liquids with the intention to provide consumers with happy, healthy and potentially curative products. URVape's plans include the installation of its own laboratory along with a "clean room" for production of its products. The goal is to become the market leader of safe vaping materials. To that end, URVape has Trademarked "SafeVape" for use in describing the technologies utilized in bringing both devices and e-liquids to the marketplace.

The E-cigarette, Cannabis and Herbal vaping industry is an ever growing and evolving industry. Business models need to be constantly adjusted and configured based on all moving parts. But we are fortunate to be part of this historical moment in time where consumers around the globe will finally have access to natural plant derivatives to enhance their health and enjoyment without the inherent side effects of synthetic medicines. URVape will be part of that historical moment creating technologies for the delivery of its specialized, researched products. With the decriminalization and legalization of cannabis for medicinal and recreational use in many states and countries throughout the world the adoption of electronic vaporizing by the world's 1.2 Billion smokers - eCig or vaporizer market is the fastest market within the tobacco (free) industry and estimated to be a multi-billion-dollar industry within a few years.

B. Date and State (or Jurisdiction) of Incorporation:

The Company was initially incorporated in the State of Oregon in 06-22-1987.

C. the issuer's primary and secondary SIC Codes;

8071 – Medical Laboratory

D. the issuer's fiscal year end date;

03/31

E. principal products or services, and their markets;

CB Scientific Inc. (CBSC), an Oregon corporation, through its subsidiaries, designs, develops and manufactures Life Science Analytical Tools and Devices, laboratory services, personal analytical kits and devices and CBD hemp oil and nutraceutical formulations for growers, care takers, dispensaries and companies worldwide. CB Scientific, through its subsidiaries, provides personal and professional THC and CBD test kits, pharmaceutical



grade CBD oil solutions, SafeVape vaporizers for legal medicinal & recreational cannabis. CB Scientific and its subsidiaries do not grow, distribute or sell marijuana.

7) Describe the Issuer's Facilities

The Company operates out of 13,000 sf of office space shared by the principals at an allocated cost of \$ 2,500 per month for a lease term of two years. The space allows the company to operate its lab, corporate offices and access to a vast sf of warehouse and office space for expansion, shipping and manufacturing.

8) Officers, Directors, and Control Persons

- A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Saeed (Sam) Talari, Chairman & Acting CEO – Control Person
10901 Roosevelt Blvd, Suite 1000c,
Saint Petersburg, FL, 33716

John Verghese, CTO - Director
10901 Roosevelt Blvd, Suite 1000c,
Saint Petersburg, FL, 33716

Dr. Bobban Subhadra, COO & President
10901 Roosevelt Blvd, Suite 1000c,
Saint Petersburg, FL, 33716

Mr. Talari became the Chairman & CEO, Principle Financial Officer, Principle Accounting Officer and Chief Financial Officer of CB Scientific, Inc. after the asset purchase by CB Scientific, Inc. (Oregon) of CB Scientific, Inc. of Colorado. Mr. Talari owns indirectly 46,255,263 shares of common stock and 10,000,000 shares of preferred through Talari Industries, LLC.

On January 1, 2016, the Company entered into a three-year Employment Agreement with Mr. Talari, the Company's Acting Chief Executive Officer, and Company's director. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of \$8,500 per month, with a 5% increase per annum and (b) all group insurance plans and other benefit plans and programs made available to the Company's management employees.

On February 24, 2017, the Company entered into a three-year Employment Agreement with Mr. Subhadra, the Company's COO and President. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of \$5,000 per month, with a 5% increase per annum and (b) all group insurance plans and other benefit plans and programs made available to the Company's management employees.



On January 01, 2017, the Company entered into a three-year Employment Agreement with Mr. Verghese, the Company's CTO, and Company's director. The Agreement is automatically extended for additional one-year periods without further action from the Company or the executive, unless notice of termination is given by either party within 90 days of the end of any periods. The Agreement provides for (a) a base salary of \$5,000 per month, with a 5% increase per annum and (b) all group insurance plans and other benefit plans and programs made available to the Company's management employees.

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Talari Industries, LLC.*
3637 4th Street North, Suite 330,
Saint Petersburg, FL, 33704
46,255,263 shares of Common stock

FutureWorld Corp.*
10901 Roosevelt Blvd, Suite 1000c,
Saint Petersburg, FL, 33716
8,000,448 shares of Common stock



* Sam Talari is the sole controlling director of Talari Industries, LLC and the CEO of FutureWorld Corp and CB Scientific.

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Securus Law Group, P.A.
13046 Racetrack Road #234
Tampa, FL 33626
Phone: (888) 914-4144
Fax: (888) 783-4712

Accountant or Auditor

Malone Bailey LLP
9801 Westheimer Road
Suite 1100
Houston, TX 77042

Investor Relations Consultant

Atlanta Capital Partners LLC
235 Peachtree Street NE
Suite 400
Atlanta, GA 30303
(866) 692-6847 U.S. and Canada
(404) 856-9157 Local
(404) 393-7074 Fax
info@atlcp.com

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

None

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Saeed (Sam) Talari, certify that:

1. I have reviewed this information & quarterly statement of CB Scientific Inc.;



2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

February 28, 2017

“/s/” Sam Talari

Chairman & Acting CEO and Chief Financial Officer
CB Scientific Inc.